Delta Asia International (6762) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 達亞

Delta Asia International (6762) reported revenue of NT$53.8 million for Oct 2026, -2.0% year on year and -21.3% from the previous month. Revenue for Jan–Oct 2026 was NT$627.2 million (+6.5% year on year).

In Oct 2026, it ranked No. 95 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$53.5 million24/10Nov 2024 NT$61.6 millionDec 2024 NT$61.8 millionJan 2025 NT$51.5 millionFeb 2025 NT$51 million25/02Mar 2025 NT$61.1 millionApr 2025 NT$70.1 millionMay 2025 NT$62.3 millionJun 2025 NT$62.7 million25/06Jul 2025 NT$61.4 millionAug 2025 NT$60.1 millionSep 2025 NT$54 millionOct 2025 NT$54.9 million25/10Nov 2025 NT$54.6 millionDec 2025 NT$50.4 millionJan 2026 NT$51.3 millionFeb 2026 NT$32.5 million26/02Mar 2026 NT$52 millionApr 2026 NT$60.2 millionMay 2026 NT$70.5 millionJun 2026 NT$76.4 million26/06Jul 2026 NT$80.9 millionAug 2026 NT$81.5 millionSep 2026 NT$68.3 millionOct 2026 NT$53.8 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$53.8 million-2.0%-21.3%
Sep 2026NT$68.3 million+26.5%-16.1%
Aug 2026NT$81.5 million+35.5%+0.7%
Jul 2026NT$80.9 million+31.8%+5.9%
Jun 2026NT$76.4 million+21.8%+8.4%
May 2026NT$70.5 million+13.0%+17.1%
Apr 2026NT$60.2 million-14.2%+15.6%
Mar 2026NT$52 million-14.9%+60.2%
Feb 2026NT$32.5 million-36.4%-36.7%
Jan 2026NT$51.3 million-0.4%+1.8%
Dec 2025NT$50.4 million-18.5%-7.8%
Nov 2025NT$54.6 million-11.3%-0.4%
Oct 2025NT$54.9 million+2.5%+1.6%
Sep 2025NT$54 million-4.5%-10.2%
Aug 2025NT$60.1 million+3.1%-2.0%
Jul 2025NT$61.4 million+21.0%-2.1%
Jun 2025NT$62.7 million+34.0%+0.6%
May 2025NT$62.3 million+22.7%-11.0%
Apr 2025NT$70.1 million+75.0%+14.7%
Mar 2025NT$61.1 million+104.0%+19.7%
Feb 2025NT$51 million+41.9%-0.9%
Jan 2025NT$51.5 million+49.8%-16.7%
Dec 2024NT$61.8 million+101.4%+0.4%
Nov 2024NT$61.6 million+98.4%+15.0%
Oct 2024NT$53.5 million+22.2%-5.4%

Jan–Oct 2026 cumulative: NT$627.2 million (+6.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Delta Asia International vs PEC / Delta Asia International vs Lotus Pharm / Delta Asia International vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16